stoxline Quote Chart Rank Option Currency Glossary
  
Phathom Pharmaceuticals, Inc. (PHAT)
5.72  -0.05 (-0.87%)    02-18 16:00
Open: 5.73
High: 6.02
Volume: 1,163,255
  
Pre. Close: 5.77
Low: 5.52
Market Cap: 391(M)
Technical analysis
2025-02-18 4:46:12 PM
Short term     
Mid term     
Targets 6-month :  7.55 1-year :  8.46
Resists First :  6.47 Second :  7.25
Pivot price 5.84
Supports First :  5.21 Second :  4.33
MAs MA(5) :  5.59 MA(20) :  6.07
MA(100) :  10.7 MA(250) :  11.21
MACD MACD :  -0.5 Signal :  -0.6
%K %D K(14,3) :  32.7 D(3) :  24.3
RSI RSI(14): 39
52-week High :  19.7 Low :  5.21
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PHAT ] has closed above bottom band by 41.1%. Bollinger Bands are 64.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 51 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 6.02 - 6.05 6.05 - 6.08
Low: 5.45 - 5.48 5.48 - 5.51
Close: 5.67 - 5.72 5.72 - 5.76
Company Description

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Headline News

Tue, 18 Feb 2025
Phathom Pharmaceuticals CFO Molly Henderson sells shares worth $43,370 - MSN

Mon, 17 Feb 2025
Phathom Pharmaceuticals (NASDAQ:PHAT) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat

Fri, 14 Feb 2025
Phathom stock gains after Cantor bullish view (PHAT:NASDAQ) - Seeking Alpha

Fri, 14 Feb 2025
symbol__ Stock Quote Price and Forecast - CNN

Fri, 07 Feb 2025
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Bought by Jennison Associates LLC - MarketBeat

Fri, 31 Jan 2025
Further weakness as Phathom Pharmaceuticals (NASDAQ:PHAT) drops 12% this week, taking five-year losses to 81% - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 68 (M)
Shares Float 56 (M)
Held by Insiders 4.3 (%)
Held by Institutions 99.4 (%)
Shares Short 14,630 (K)
Shares Short P.Month 14,950 (K)
Stock Financials
EPS -5.74
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -2.75
Profit Margin 0 %
Operating Margin -433 %
Return on Assets (ttm) -57.7 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0.32
Sales Per Share 0.38
EBITDA (p.s.) -4.2
Qtrly Earnings Growth 0 %
Operating Cash Flow -247 (M)
Levered Free Cash Flow -180 (M)
Stock Valuations
PE Ratio -1
PEG Ratio 0
Price to Book value -2.09
Price to Sales 14.88
Price to Cash Flow -1.59
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android